Califf Hints At Labeling Changes For Opioids And Chronic Pain

 
• By Sarah Karlin-Smith

Califf also said the agency is open to endpoints other than abstinence for new opioid use disorder treatments at the fourth annual NIH HEAL Initiative Investigator Meeting. 

person in pain
The FDA Commissioner Highlighted a New CDC Report Citing ‘No Evidence’ Of Chronic Opioid Benefit When Discussing Potential Labeling Changes. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards